HIV remains a significant global public health challenge with approximately 38 million people living with HIV worldwide. Prevention of vertical transmission remains critical in reducing the burden of HIV in children. The use of effective antiretroviral therapy has significantly reduced the incidence of vertical transmission. However, challenges and gaps remain in providing optimal care and treatment for pregnant and breastfeeding women and newborns, particularly in resource-limited settings. Long-acting HIV prevention and treatment options have the potential to revolutionize HIV care and address some of these gaps by providing simplified, effective, and convenient alternatives to current treatment options. However, the development and approval of long-acting solutions for pregnant and breastfeeding women and newborns face numerous challenges, including limited research on safety and efficacy. To address these challenges and improve access, there is a need for increased investment in research, approaches to the delivery of treatment and prevention, and streamlined regulatory processes. Therefore, exploring the challenges and opportunities in embedding long-acting options for these populations is critical to improving their care and reducing the burden of HIV in children. Convened by the IAS Corporate Partnership Programme (CPP), the session aims to bring together stakeholders from the pharmaceutical industry, academia, non-governmental organizations, and community to discuss the current obstacles to developing and implementing long-acting HIV prevention and treatment options and provide a platform for sharing experiences and best practices.